Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.44 |
| ▸ | WNT3A | P56704 | 3/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29562338 | 1.00 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL21591507 | 0.86 | CYP1A2 (0.58) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL6450219 | 0.84 | KDM4E (0.48) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| Tert-Butyl Formate SCHEMBL27926204 | 0.82 | KDM4E (0.44) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL3839330 | 0.81 | KDM4E (0.47) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL254885 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL16182225 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL702375 | 0.79 | PRMT5 (0.61) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL2227955 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL960151 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| CN-112778203-B | Process for the preparation of 1H-indazole-3-carboxylic acid derivatives and granisetron and lonidamine | 兰州交通大学 | 2022-02-15 | — | — | CN | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-112778203-A | Process for the preparation of 1H-indazole-3-carboxylic acid derivatives and granisetron and lonidamine | 兰州交通大学 | 2021-05-11 | — | — | CN | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005009958-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2005-01-13 | — | — | US | disclosed |
| EP-1442034-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-08-04 | — | — | EP | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035644-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS KDR PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | WO | disclosed |
| US-4008070-A | ALKYL 5-HALO-1H-INDAZOLE-3-ACETATE | NISSAN CHEMICAL INDUSTRIES CO., LTD. (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | KDM4E 2008/4885GAA 1101/4885PDPK1 3587/4885 |
| US-20050038246-A1 | PPAR active compounds | PPARG, PPARD, PPARA | KDM4E 2954/4885GAA 1372/4885PDPK1 258/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | KDM4E 645/4885GAA 352/4885PDPK1 216/4885 |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885GAA 741/4885PDPK1 2650/4885 |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885GAA 741/4885PDPK1 2650/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885GAA 741/4885PDPK1 2650/4885 |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | KDR, MUSK, FLT4 | KDM4E 1001/4885GAA 3463/4885PDPK1 616/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | KDM4E 215/4885GAA 210/4885PDPK1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.